TY - JOUR
T1 - Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study
AU - Zuily, Stephane
AU - de Laat, Bas
AU - Mohamed, Shirine
AU - Kelchtermans, Hilde
AU - Shums, Zakera
AU - Albesa, Roger
AU - Norman, Gary L.
AU - Lamboux-Matthieu, Claire
AU - Rat, Anne-Christine
AU - Ninet, Jacques
AU - Magy-Bertrand, Nadine
AU - Pasquali, Jean-Louis
AU - Lambert, Marc
AU - Lorcerie, Bernard
AU - Kaminsky, Pierre
AU - Guillemin, Francis
AU - Regnault, Veronique
AU - Wahl, Denis
PY - 2015/11
Y1 - 2015/11
N2 - Objective. To investigate the validity of the global APS score (GAPSS) to predict thrombosis in patients with autoimmune diseases. Methods. This prospective cohort study included consecutive patients with aPL or SLE. aPL, aPS-PT and GAPSS were determined. A Cox proportional hazards model assessed the validity of GAPSS and identified other potential independent predictors of thrombosis. Results. One hundred and thirty-seven patients [43.5 (S.D. 15.4) years old; 107 women] were followed up for a mean duration of 43.1 (S.D. 20.7) months. Mean GAPSS was significantly higher in patients who experienced a thrombotic event compared with those without [10.88 (S.D. 5.06) vs 8.15 (S.D. 5.31), respectively, P = 0.038]. In univariate analysis, age [hazard ratio (HR) = 1.04 (95% CI 1.01, 1.08)] and GAPSS above 16 [HR = 6.86 (95% CI 1.90, 24.77)] were each significantly associated with thrombosis during follow-up, while history of arterial thrombosis [HR = 2.61 (95% CI 0.87, 7.82)] failed to reach significance. Among aPL assays, IgG aPS/PT-a component of the GAPSS-was significantly associated with thrombosis [HR = 2.95 (95% CI 1.02, 8.51)]. In multivariate analysis, GAPSS above 16 remained the only significant predictor of thrombosis [HR = 6.17 (95% CI 1.70, 22.40)]. Conclusion. This first external validation study confirmed that GAPSS can predict thrombosis in patients with aPL and associated autoimmune diseases.
AB - Objective. To investigate the validity of the global APS score (GAPSS) to predict thrombosis in patients with autoimmune diseases. Methods. This prospective cohort study included consecutive patients with aPL or SLE. aPL, aPS-PT and GAPSS were determined. A Cox proportional hazards model assessed the validity of GAPSS and identified other potential independent predictors of thrombosis. Results. One hundred and thirty-seven patients [43.5 (S.D. 15.4) years old; 107 women] were followed up for a mean duration of 43.1 (S.D. 20.7) months. Mean GAPSS was significantly higher in patients who experienced a thrombotic event compared with those without [10.88 (S.D. 5.06) vs 8.15 (S.D. 5.31), respectively, P = 0.038]. In univariate analysis, age [hazard ratio (HR) = 1.04 (95% CI 1.01, 1.08)] and GAPSS above 16 [HR = 6.86 (95% CI 1.90, 24.77)] were each significantly associated with thrombosis during follow-up, while history of arterial thrombosis [HR = 2.61 (95% CI 0.87, 7.82)] failed to reach significance. Among aPL assays, IgG aPS/PT-a component of the GAPSS-was significantly associated with thrombosis [HR = 2.95 (95% CI 1.02, 8.51)]. In multivariate analysis, GAPSS above 16 remained the only significant predictor of thrombosis [HR = 6.17 (95% CI 1.70, 22.40)]. Conclusion. This first external validation study confirmed that GAPSS can predict thrombosis in patients with aPL and associated autoimmune diseases.
KW - antiphospholipid syndrome
KW - global APS score
KW - anti-phosphatidylserine/prothrombin antibodies
KW - systemic lupus erythematosus
KW - thrombosis
U2 - 10.1093/rheumatology/kev238
DO - 10.1093/rheumatology/kev238
M3 - Article
C2 - 26163690
VL - 54
SP - 2071
EP - 2075
JO - Rheumatology
JF - Rheumatology
SN - 1462-0324
IS - 11
ER -